Lung transplantation - Opportunities for research and clinical advancement

被引:70
作者
Wilkes, DS
Egan, TM
Reynolds, HY
机构
[1] NHLBI, DLD, Bethesda, MD 20892 USA
[2] Univ N Carolina, Chapel Hill, NC 27514 USA
[3] Indiana Univ, Sch Med, Indianapolis, IN USA
关键词
allograft dysfunction; infection; ischemia-reperfusion injury; lung transplantation; obliterative bronchiolitis; rejection;
D O I
10.1164/rccm.200501-098WS
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Lung transplantation is the only definitive therapy for many forms of end-stage lung diseases. However, the success of lung transplantation is limited by many factors: (1) Too few lungs available for transplantation due to limited donors or injury to the donor lung; (2) current methods of preservation of excised lungs do not allow extended periods of time between procurement and implantation; (3) acute graft failure is more common with lungs than other solid organs, thus contributing to poorer short-term survival after lung transplant compared with that for recipients of other organs; (4) lung transplant recipients are particularly vulnerable to pulmonary infections; and (5) chronic allograft dysfunction, manifest by bronchiolitis obliterans syndrome, is frequent and limits long-term survival. Scientific advances may provide significant improvements in the outcome of lung transplantation. The National Heart, Lung, and Blood Institute convened a working group of investigators on June 14-15, 2004, in Bethesda, Maryland, to identify opportunities for scientific advancement in lung transplantation, including basic and clinical research. This workshop provides a framework to identify critical issues related to clinical lung transplantation, and to delineate important areas for productive scientific investigation.
引用
收藏
页码:944 / 955
页数:12
相关论文
共 160 条
[1]   Heterologous immunity provides a potent barrier to transplantation tolerance [J].
Adams, AB ;
Williams, MA ;
Jones, TR ;
Shirasugi, N ;
Durham, MM ;
Kaech, SM ;
Wherry, EJ ;
Onami, T ;
Lanier, JG ;
Kokko, KE ;
Pearson, TC ;
Ahmed, R ;
Larsen, CP .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (12) :1887-1895
[2]  
ADAMSON RH, 1998, AM J PHYSIOL, V274, pH1855
[3]   MACROLIDE ANTIBIOTICS AS ANTIINFLAMMATORY AGENTS - ROXITHROMYCIN IN AN UNEXPECTED ROLE [J].
AGEN, C ;
DANESI, R ;
BLANDIZZI, C ;
COSTA, M ;
STACCHINI, B ;
FAVINI, P ;
DELTACCA, M .
AGENTS AND ACTIONS, 1993, 38 (1-2) :85-90
[4]  
Aitchison J. D., 2002, Journal of Heart and Lung Transplantation, V21, P57, DOI 10.1016/S1053-2498(01)00441-7
[5]   Functional assessment of non-heart-beating donor lungs: prediction of post-transplant function [J].
Aitchison, JD ;
Orr, HE ;
Flecknell, PA ;
Kirby, JA ;
Dark, JH .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2001, 20 (01) :187-194
[6]   Modified reperfusion and ischemia-reperfusion injury in human lung transplantation [J].
Ardehali, A ;
Laks, H ;
Russell, H ;
Levine, M ;
Shpiner, R ;
Lackey, S ;
Ross, D .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2003, 126 (06) :1929-1934
[7]   Role of CXCL9/CXCR3 chemokine biology during pathogenesis of acute lung allograft rejection [J].
Belperio, JA ;
Keane, MP ;
Burdick, MD ;
Lynch, JP ;
Zisman, DA ;
Xue, YY ;
Li, KW ;
Ardehali, A ;
Ross, DJ ;
Strieter, RM .
JOURNAL OF IMMUNOLOGY, 2003, 171 (09) :4844-4852
[8]   Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome [J].
Belperio, JA ;
Keane, MP ;
Burdick, MD ;
Lynch, JP ;
Xue, YY ;
Li, KW ;
Ross, DJ ;
Strieter, RM .
JOURNAL OF IMMUNOLOGY, 2002, 169 (02) :1037-1049
[9]   The role of the CC chemokine, RANTES, in acute lung allograft rejection [J].
Belperio, JA ;
Burdick, MD ;
Keane, MP ;
Xue, YY ;
Lynch, JP ;
Daugherty, BL ;
Kunkel, SL ;
Strieter, RM .
JOURNAL OF IMMUNOLOGY, 2000, 165 (01) :461-472
[10]  
Bemelman F J, 1994, Transpl Immunol, V2, P47, DOI 10.1016/0966-3274(94)90077-9